Connecting Patients, Families, and Advocates

10.11.13 | By

Every day, our industry strives to connect patients, families and advocates from across the globe who share our common goals of preventing diseases, improving health and saving lives. Those strong voices of innovators and stakeholders working tirelessly to address pressing medical challenges, and many medical breakthroughs wouldn’t be possible today or in the future without them.

Greater Integration of Patient Input in Regulatory Decision-Making

10.10.13 | By

In the last 20 years, the Prescription Drug User Fee Act (PDUFA) has resulted in timelier patient access to more than 1,500 new drugs and biologics, decreasing review times for these treatments by more than 60 percent.

Drugfree.org CEO Steve Pasierb on The Medicine Abuse Project

10.09.13 | By

We’re excited to host a guest blog post by Steve Pasierb, the passionate CEO of The Partnership at Drugfree.org. We’ve been longtime partners with The Partnership, and Steve’s blog will be the first of regular updates about what’s new in The Partnership at Drugfree.org’s world.

Conversations: Medicines in Development for Rare Disease

10.08.13 | By

The world’s biopharmaceutical research companies continually strive to develop new medicines that prevent diseases, improve patient health, and help save lives.  There are currently more than 5,000 medicines in development globally.

Week in Review

10.04.13 | By

The significant disease progress we've made reminds us to not only recognize and appreciate what we've already accomplished on behalf of patients, but also to look into the future and determine what more can be done.

The Puzzle, The Partners, The Path Forward

10.02.13 | By

The best and the brightest spanning the innovation ecosystem have been trying for years to unlock the mysteries of Alzheimer’s disease with the common goals of delaying, treating or outright preventing progression of the disease. Further, there are a number of public and private initiatives underway and no shortage of related conferences and meetings.

One Year Anniversary of PDUFA V

09.30.13 | By

In 1992, under the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) began collecting fees from biopharmaceutical companies to provide much needed resources to keep new medicines moving through the approval process and into the hands of patients. 

Conversations on Medicare Part D

09.30.13 | By

In 2003, through the Medicare Modernization Act, Congress established the Medicare prescription drug benefit - better known as Part D. Ten years later, at a cost significantly below initial estimates, the program is successfully providing affordable access to prescription drugs for more than 30 million seniors and people with disabilities.

Recent Progress is Staggering

09.27.13 | By

From programs that provide access to medicines, to the development of innovative new treatments, the recent progress we’ve made is staggering.

Patient Health, Innovation and the Protections Needed

09.27.13 | By

Millions of patients around the world depend on innovative medicines to help them live long, healthy lives. Every time I travel to a different country, I am reminded of this fact. Just last week in Tokyo, PhRMA EVP for Advocacy Chip Davis specifically addressed how the innovative new medicines our member companies develop have enhanced the country’s health care system.

Pages

Subscribe to RSS - Opinion